Anthera Pharmaceuticals, Inc.
ANTH · OTC
3/31/2018 | 12/31/2017 | 9/30/2017 | 6/30/2017 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.01 | 0.01 | -0.00 |
| FCF Yield | -135.03% | -26.51% | -39.32% | -61.59% |
| EV / EBITDA | 0.11 | -2.32 | -1.23 | -0.62 |
| Quality | ||||
| ROIC | -102.16% | 926.92% | -133.08% | -2,504.05% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.21 | 0.65 | 0.98 | -32.31 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -49.86% | -1.00% | 38.71% | 29.42% |
| Safety | ||||
| Net Debt / EBITDA | 0.75 | 0.24 | 0.77 | 1.31 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -22,234.87 | -21,538.86 | -14,877.13 | -25,257.32 |